Whenever there are deviations from homeostasis in the body’s functions, the endocannabinoid system is activated and begins to respond accordingly by synthesizing endocannabinoids, which act as neurotransmitters.
When the body creates neurotransmitters for the endocannabinoid system, they are picked up by specialized cannabinoid receptors, which sit on the surface of cells. These receptors are found in a wide range of physiological regions, such as in the immune system:
Organs and glands
The brain (most significantly)
Like a key fits into a lock, endocannabinoids interact with these receptors and transmit information about changing conditions to kick-start a response, with the goal of helping the body achieve homeostasis, or equilibrium, within the body despite outside influences (Alger, 2013).
The endocannabinoid system’s receptor sites include CB1 and CB2 receptor variants, which respond differently to various cannabinoids (Pacher et al, 2006). CB1 receptors are most prevalent in the central nervous system and are linked to the following benefits:
Inhibition of tumors
Balance of immune system
Modulation of stress and anxiety
CB2 receptors are found mostly on cells in the immune system and seem to dominate in fighting inflammation and damage to tissue. Some cells can even contain both types of receptors, each responsible for a different function.
There are two major endocannabinoids – 2-arachidonoylglycerol (2-AG) and Anandamide (AEA).
2-AG is considered a full agonist of both CB1 and CB2 receptors. This means that it binds with, and fits well inside, both receptors to activate them to stimulate a physiological response.
Anandamide is considered a partial agonist of both receptors, because, while it binds with and activates the receptors, it doesn’t fit as well inside them and subsequently doesn’t trigger such a powerful physiological response (Parcher, Batkai & Kunos, 2006).
Once the function that had deviated from homeostasis returns to equilibrium and the endocannabinoids are no longer needed, the third piece of the system – the metabolic enzymes – breaks down and degrades them.
Fatty acid amide hydrolase (FAAH) degrades Anandamide, and monoacylglycerol lipase (MAGL) breaks down 2-AG. By eliminating the endocannabinoids, the endocannabinoid system “turns off” the molecular signals and ends whatever physiological activity it had stimulated.
By partnering with an established analysis laboratory of 30 years, we now have the exclusive ability to begin analyze the data provided by our patients from a much more detailed perspective, allowing us to work with patient data on a much more advanced level.
Our exclusive methodology allows us to isolate the Endocannabiniod system and scan search for other health factors per patient, then educate and advise on trackable relief by adding CBD.
This is how it works.
1. We analyze a sample provided by the patient with our proprietary analysis process.
2. Using the data collected, we work with our doctors and affiliates to offer proprietary information promoting proper balance and delivery of Hemp products for that patient’s symptoms based on test results and related studies.
3. Then track the results following the introduction of CBD, each patient will have their own personalized information with which we can help them become their own advocate to creating a more complete balance within their body.
Other companies currently in the industry will realistically need to seek out these same procedures and protocols due to testing regulations that will inevitably be required.
With the overwhelming number of patients and veterans we work with that suffer from PTSD, Chronic Pain, Fibromyalgia, epilepsy, Alzheimer’s, Parkinson’s disease and many others, we have strategically positioned ourselves to utilize this new technology in a way that allows us to better understand each ailment individually and stay ahead of the curve becoming the new standard in the industry for clinical Hemp testing.